Accredited E-Newsletter Series

The Evolving Era of Novel Therapies in Multiple Myeloma
The Evolving Era of Novel Therapies in Multiple Myeloma
CME, CPE
Joshua Richter, MD
Release Date: November 15, 2016
Expiration Date: November 15, 2017

The evolving role of biological and molecular markers in the diagnosis and prognostication of multiple myeloma supports a more accurate and individualized assessment of a patient's risk-level and subsequent selection of treatment. Through an overview of the myeloma-defining events that comprise the revised ISS, and discussion of the correlation between specific cytogenetic abnormalities and response to treatment, participants will gain greater insight into the application of these diagnostic, prognostic and potentially predictive markers in the treatment of their patients with multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No Credit
 
Maximizing Prognostic Benefit: Risk-adaptive Approaches in Multiple Myeloma
Maximizing Prognostic Benefit: Risk-adaptive Approaches in Multiple Myeloma
CME, CPE
Evangelos Terpos, MD, PhD
Release Date: September 20, 2016
Expiration Date: September 20, 2017

In past years, several risk stratification models have been developed for prognosticating patients with multiple myeloma (MM). Recent updates and published consensus to the risk stratification process has led to recommended changes within current practice. Dr. Evangelos Terpos offers clinical expert recommendations concerning risk-adaptive therapeutic strategies in patients with MM, emphasizing how determination of prognosis is a critical component in identifying treatments specific for an individual patient’s unique risk level. Dr. Terpos also discusses clinical pearls for incorporating risk-adaptive approaches in a busy practice setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.

Begin, Earn CreditView Only, No Credit
 
A Practical Guide to Relapsed/Refractory Multiple Myeloma
A Practical Guide to Relapsed/Refractory Multiple Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: July 19, 2016
Expiration Date: July 19, 2017

The treatment landscape for relapsed/refractory multiple myeloma (RRMM) has become more complex with the availability of next-generation drugs, targeted agents, and immunotherapy. In this activity, Dr. Saad Usmani, Chief of the Plasma Cell Disorders Program and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute, provides an overview of the novel lenalidomide-, bortezomib-, and carfilzomib-based regimens for relapsed patients. In addition to a summary of study rationales and relevant phase III clinical trial data, Dr. Usmani provides guidance for the real-world application of these regimens and recommendations for patient selection to optimize outcomes in the relapsed setting.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Updates in Clinical Practice: New Bone Assessment Criteria
Updates in Clinical Practice: New Bone Assessment Criteria
CME, CPE
Evangelos Terpos, MD, PhD
Release Date: May 25, 2016
Expiration Date: May 25, 2017

The revised International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma have been updated to specifically identify patients who may benefit from early treatment when prognosis is more favorable. The new criteria include myeloma-defining events in the diagnosis of active myeloma, including key changes to bone assessment criteria. Dr. Evangelos Terpos, Associate Professor of Hematology at the University of Athens School of Medicine, provides an overview of the updated criteria, focusing on the impact on bone assessments, and shares clinical expertise in choosing the best imaging technique for specific patient types and assessment goals.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
Begin, Earn CreditView Only, No Credit
 
Minimizing Non-adherence and Improving Compliance in Multiple Myeloma
Minimizing Non-adherence and Improving Compliance in Multiple Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: April 18, 2016
Expiration Date: April 18, 2017

In multiple myeloma (MM), the emergence of several oral agents and the increased use of maintenance/continuous therapy could result in more treatment non-adherence and therefore reduced efficacy. Patient-related, treatment-related and clinician-related factors can all contribute to non-adherence and should be understood by health care providers, the goal being to gauge the patient’s risk for inadequate dosing. This CE activity discusses the potential for non-adherence to myeloma therapy and aims to identify ways that clinicians can ameliorate this risk.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
A Clinical Practice Guide to Diagnosing Multiple Myeloma with Expansion of Myeloma Defining Events to Include SLiM
A Clinical Practice Guide to Diagnosing Multiple Myeloma with Expansion of Myeloma Defining Events to Include SLiM
CME, CPE
Joshua Richter, MD
Release Date: February 26, 2016
Expiration Date: February 26, 2017

Prior to developing clinical symptoms, patients with multiple myeloma will progress through the asymptomatic stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). For asymptomatic patients, current diagnostic criteria quantify the underlying disease burden and provide insight on the risk of progression to active MM. This activity will review best practices in the diagnosis and initial monitoring of patients with MGUS, SMM, and active MM to support the delivery of timely intervention in appropriate patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
How Long Should I Continue Maintenance Therapy?
How Long Should I Continue Maintenance Therapy?
CME, CPE
Marie Sabo Recine, MS, and Eugene R. Tombler, PhD – Contributing authors
Release Date: April 16, 2014
Expiration Date: April 16, 2015

Reviewed: January 17, 2017 for clinical relevance; CE is expired.


This activity reviews the available clinical data regarding duration of maintenance therapy and the efficacy and safety of novel agents when used in this treatment setting, including data regarding tailoring therapy based on individual patient risk factors as well as recommendations of various consensus guidelines and evidence-based clinical expert recommendations.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
View Only, CE Expired